Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
- Author(s)
- Kostos, L; Buteau, JP; Hofman, MS; Azad, AA;
- Journal Title
- Therapeutic Advances in Medical Oncology
- Publication Type
- Review
- Abstract
- [(177)Lu]Lu-PSMA has recently been approved for use in the post-taxane, post-novel hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a beta-emitting radioligand targeting prostate-specific membrane antigen (PSMA), it delivers radiation to cells expressing PSMA on their surface. In pivotal clinical trials, patients were selected for this treatment based on positron emission tomography (PET)/CT imaging, requiring PSMA-avid disease with no evidence of discordant disease on 2-[(18)F]fluoro-2-deoxy-D-glucose PET/CT or contrast CT scan. Despite exhibiting an optimal imaging phenotype, the response for many patients is not durable, and a minority do not respond to [(177)Lu]Lu-PSMA at all. Disease progression is inevitable even for those who achieve an exceptional initial response. Reasons for both primary and acquired resistance are largely unknown; however, they are likely due to the presence of underlying PSMA-negative disease not identified on imaging, molecular factors conferring radioresistance, and inadequate delivery of lethal radiation, particularly to sites of micrometastatic disease. Biomarkers are urgently needed to optimize patient selection for treatment with [(177)Lu]Lu-PSMA by identifying those who are most and least likely to respond. Retrospective data support using several prognostic and predictive baseline patient- and disease-related parameters; however, robust prospective data is required before these can be translated into widespread use. Further, early on-treatment clinical parameters (in addition to serial prostate-specific antigen [PSA] levels and conventional restaging imaging) may serve as surrogates for predicting treatment response. With little known about the efficacy of treatments given after [(177)Lu]Lu-PSMA, optimal treatment sequencing is paramount, and biomarker-driven patient selection will hopefully improve treatment and survival outcomes.
- Publisher
- Sage
- Keywords
- 177Lu-PSMA; biomarker; castration-resistant prostate cancer; radioresistance
- Department(s)
- Medical Oncology; Cancer Imaging
- PubMed ID
- 37323184
- Publisher's Version
- https://doi.org/10.1177/17588359231179309
- Open Access at Publisher's Site
https://doi.org/10.1177/17588359231179309- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-28 07:45:36
Last Modified: 2023-09-28 07:46:07